Publications by authors named "S Daminet"
Chronic Kidney Disease (CKD) is one of the most common conditions affecting felines, yet the metabolic alterations underlying its pathophysiology remain poorly understood, hindering progress in identifying biomarkers and therapeutic targets. This study aimed to provide a comprehensive view of metabolic changes in feline CKD across conserved biochemical pathways and evaluate their progression throughout the disease continuum. Using a multi-biomatrix high-throughput metabolomics approach, serum and urine samples from CKD-affected cats ( = 94) and healthy controls ( = 84) were analyzed with ultra-high-performance liquid chromatography-high-resolution mass spectrometry.
View Article and Find Full Text PDFBackground: Although gut-derived uremic toxins are increased in azotemic chronic kidney disease (CKD) in cats and implicated in disease progression, it remains unclear if augmented formation or retention of these toxins is associated with the development of renal azotemia.
Objectives: Assess the association between gut-derived toxins (ie, indoxyl-sulfate, p-cresyl-sulfate, and trimethylamine-N-oxide [TMAO]) and the onset of azotemic CKD in cats.
Animals: Forty-eight client-owned cats.
Background: Borderline proteinuria is associated with decreased survival in cats with azotemic chronic kidney disease (CKD).
Objectives: Determine the clinical importance of borderline proteinuria in nonazotemic cats.
Animals: A total of 201 healthy client-owned cats ≥7 years of age; 150 nonproteinuric (urinary protein : creatinine ratio [UPC] <0.
Background: The high doses of radioiodine-131 (I) and, subsequently, the high radioactive burden for dog and environment warrants optimization of I therapy in dogs with thyroid carcinoma (TC).
Hypothesis/objectives: To evaluate the effect of a revised protocol with recombinant human thyroid stimulating hormone (rhTSH) on tumor radioactive iodine uptake (RAIU) in dogs with TC.
Animals: Nine client-owned dogs diagnosed with TC.